KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BeOne Medicines (ONC) Net Margin (2016 - 2025)

BeOne Medicines (ONC) has disclosed Net Margin for 11 consecutive years, with 16.23% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 2970.0% to 16.23% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.68%, a 2560.0% increase, with the full-year FY2025 number at 8.6%, up 2552.0% from a year prior.
  • Net Margin was 16.23% for Q4 2025 at BeOne Medicines, up from 8.84% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 27.57% in Q3 2023 to a low of 320.24% in Q2 2021.
  • A 5-year average of 78.75% and a median of 45.67% in 2024 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: surged 74050bps in 2021, then tumbled -15260bps in 2022.
  • BeOne Medicines' Net Margin stood at 283.14% in 2021, then soared by 63bps to 105.74% in 2022, then soared by 45bps to 57.94% in 2023, then skyrocketed by 77bps to 13.47% in 2024, then skyrocketed by 221bps to 16.23% in 2025.
  • Per Business Quant, the three most recent readings for ONC's Net Margin are 16.23% (Q4 2025), 8.84% (Q3 2025), and 7.17% (Q2 2025).